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Recently much attention had been directed toward the significance of hyperuricemia in general population and aggravation of nephropathy. Various investigations have 
shown that elevated uric acid levels might have a deleterious 
effect, directing to endothelial dysfunction, inflammation, 
and vascular disease (1,2). The proposed mechanisms is 
that elevated uric acid initiates endothelial dysfunction 
by inhibiting nitric oxide synthetase, activating the renin-
angiotensin system and causing pro-inflammation with leads 
to endothelial dysfunction, vascular smooth muscle cell 
dysfunction, and finally contributing to atherosclerosis and 
vascular dysfunction (1–3). About 70% of uric acid is removed 
by the kidneys, hyperuricemia, therefore happens when renal 
function deteriorates. It is not fully understood that whether 
the hyperuricemia, observed in renal failure, plays a role in the 
progression of kidney failure (1–4). Recent clinical findings 
demonstrated that, the serum uric acid is narrowly linked to 
hypertension (HTN) in hyperuricemic subjects and also with 
the beginning of HTN (2–4). In fact, uric acid, as the final 
oxidation product of purine catabolism, has been associated with 
various clinical conditions such as diabetes and atherosclerotic 
disease too. Recent findings suggest that uric acid is a relevant 
and independent risk factor for kidney disease, particularly in 
patients with HTN (1–5). It was observed that hyperuricemia, 
when induced by an uricase inhibitor, initiates HTN and impairs 
nitric oxide generation in the macula densa of the glomerulus, 
while both HTN and kidney damage are reduced by inducing 
of nitric oxide (1–5). The mechanism by which uric acid may 
cause organ injury is not fully defended, nevertheless there 
is increasing evidence that dysfunction of endothelial cells 
as mentioned above is a mechanism whereby this substance 
may affect kidney function and structure. HTN is consistently 
linked to endothelial dysfunction and hyperuricemia is a strong 
predictor of HTN and blood pressure progression (1,3–5). 
Though, irrespective of kidney involvement, elevated serum 
uric acid is related with renal development of hypertension. It 
was also shown that in the adolescents with newly diagnosed 
hypertension, treatment with allopurinol resulted in lowering 
of blood pressure. On the other hand, it is well recognized 
that hyperuricemia is an independent risk factor for IgA 
nephropathy too, and appropriate treatment by allopurinol is 
a reasonable modality in this group (6). In fact, this drug can 
routinely be added to the treatment of IgA nephropathy or 
diabetics patients (4–6). Though various clinical investigations 
have shown that, lowering uric acid with allopurinol improved 
endothelial dysfunction in both hyperuricemic subjects and 
hypertensive type 2 diabetic patients with normal uric acid 
levels (3–8).We therefore suggest, further clinical studies, to 
better find the allopurinol kidney protective properties in 
diabetes, IgA nephropathy or other nephropathies.
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Implication for health policy/practice/research/medical education
Studies have shown that elevated uric acid levels have a deleterious effect, directing to endothelial 
dysfunction, inflammation, and vascular disease. Elevated uric acid initiates endothelial dysfunction by 
inhibiting nitric oxide synthetase, activating the renin-angiotensin system and causing pro-inflammation 
with leads to endothelial dysfunction, vascular smooth muscle cell dysfunction, and finally contributing to 
atherosclerosis and vascular dysfunction and aggravation of diabetic kidney disease and IgA nephropathy 
and other nephropathies. While various clinical investigations have shown that, lowering uric acid with 
allopurinol improved endothelial dysfunction in both hyperuricemic subjects and hypertensive type 2 
diabetic patients with normal uric acid levels. We therefore suggest, further clinical studies, to better find 
the allopurinol kidney protective properties in diabetes, IgA nephropathy or other nephropathies.
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